James Hippel, Chief Financial Officer of BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 statement of changes in beneficial ownership on August 19, 2026, reporting transactions dated August 17, 2026.

Key Highlights

  • Reporting person: James Hippel, CFO of BIO-TECHNE Corp
  • New RSU grants: 22,438 restricted stock units acquired on 08/17/2026 at $0, vesting in three tranches on 8/17/2027, 8/17/2028, and 8/17/2029
  • Second RSU grant: 36,459 restricted stock units acquired on 08/17/2026 at $0, vesting in full on 8/17/2029
  • Common stock beneficially owned following reported transactions: 170,183 shares (direct)
  • Stock options held: Seven tranches of stock options with exercise prices ranging from $53.60 to $120.46, covering 371,388 underlying shares in aggregate
  • Performance RSUs held: 24,062 and 29,420 units subject to performance goals vesting on 8/15/2027 and 8/15/2028, respectively

Bio-Techne CFO Receives RSU Grants and Holds Extensive Derivative Securities

According to the filing, James Hippel, serving as CFO, reported the acquisition of two tranches of restricted stock units on August 17, 2026. The first grant covers 22,438 restricted stock units, with 7,479 units scheduled to vest on each of 8/17/2027 and 8/17/2028, and 7,480 units vesting on 8/17/2029. The second grant covers 36,459 restricted stock units, all vesting on 8/17/2029. Both grants were acquired at a price of $0 per unit. The filing notes that each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

Following the reported transactions, the filing discloses that Hippel directly beneficially owns 170,183 shares of common stock. In addition to the newly granted RSUs, the filing shows existing restricted stock units in three separate tranches: 4,011 units vesting on 8/15/2027; 23,089 units split between 11/1/2026 and 11/1/2027; and 9,807 units split between 8/15/2027 and 8/15/2028. Two tranches of performance restricted stock units totaling 53,482 units are also listed, vesting conditionally on 8/15/2027 and 8/15/2028 if certain performance goals are achieved.

The filing also discloses seven tranches of stock options with exercise prices of $66.97, $120.46, $94.52, $84.61 (two tranches), $74.91, and $53.60. Several of these are described as fully exercisable, while others vest according to specified schedules through 8/15/2028. The form was signed by Andrew Nick as Attorney-in-Fact for James Hippel pursuant to a previously filed power of attorney.

What Was Disclosed

The filing reports the acquisition of 58,897 restricted stock units by BIO-TECHNE Corp's CFO on August 17, 2026, along with the CFO's total direct beneficial ownership of 170,183 common shares and extensive derivative security holdings including stock options and performance-based RSUs.